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http://www.molecular-cancer.com/content/13/1/215RESEARCH Open AccessThe DEK oncoprotein binds to highly and
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Carl Sandén1*, Linnea Järvstråt1, Andreas Lennartsson2, Per Ludvik Brattås1, Björn Nilsson1 and Urban Gullberg1Abstract
Background: The DEK gene is highly expressed in a wide range of cancer cells, and a recurrent translocation
partner in acute myeloid leukemia. While DEK has been identified as one of the most abundant proteins in human
chromatin, its function and binding properties are not fully understood.
Methods: We performed ChIP-seq analysis in the myeloid cell line U937 and coupled it with epigenetic and gene
expression analysis to explore the genome-wide binding pattern of DEK and its role in gene regulation.
Results: We show that DEK preferentially binds to open chromatin, with a low degree of DNA methylation and scarce
in the heterochromatin marker H3K9me3 but rich in the euchromatin marks H3K4me2/3, H3K27ac and H3K9ac. More
specifically, DEK binding is predominantly located at the transcription start sites of highly transcribed genes and a
comparative analysis with previously established transcription factor binding patterns shows a similarity with that of
RNA polymerase II. Further bioinformatic analysis demonstrates that DEK mainly binds to genes that are ubiquitously
expressed across tissues. The functional significance of DEK binding was demonstrated by knockdown of DEK by
shRNA, resulting in both significant upregulation and downregulation of DEK-bound genes.
Conclusions: We find that DEK binds to transcription start sites with a dual role in activation and repression of highly
and ubiquitously expressed genes.
Keywords: DEK, DEK-NUP214, ChIP-seq, shRNA, Gene expression, Euchromatin, Heterochromatin, Histone
modifications, RNA polymerase IIIntroduction
The DEK oncogene is highly expressed in many types of
cancers, including breast, ovarian, bladder, colon, and skin
cancer as well as acute myeloid leukemia [1-3]. High DEK
expression is also associated with advanced disease and
poor prognosis [4-6]. No mutations have been reported
and upregulation may occur through copy gains [7] or
transcriptional activation by upstream regulators such as
E2F-1 [1], NF-Y [8], YY-1 [8] and ERα [9]. The DEK gene
is also part of the t(6;9) chromosomal translocation result-
ing in the DEK-NUP214 fusion gene, which is found in 1%
of acute myeloid leukemias and promotes cellular prolifer-
ation and transformation [10,11].* Correspondence: carl.sanden@med.lu.se
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unless otherwise stated.What is known of the role of DEK in cancer biology is
multifaceted. The expression is generally high in rapidly
proliferating cells and knockdown of DEK by shRNA re-
duces the proliferation of cell lines from several tissues
[1,12]. Inhibition of DEK is sufficient to drive melanoma
cells into senescence whereas overexpression prolongs cel-
lular lifespan [13,14]. In several cell types, DEK expression
is reduced during cellular differentiation and depletion of
DEK promotes the differentiation of both cell lines and
primary cells [15,16]. Conversely, overexpression of DEK
causes a shift in keratinocytes from a differentiated to a
proliferative state [16]. Many studies have also implicated
DEK in apoptosis, although with differing roles depending
on the cellular context. In HeLa cells, DEK depletion leads
to apoptosis through p53 stabilization, whereas knockdown
of DEK in melanoma cells causes downregulation of the
anti-apoptotic protein MCL-1 [2,17]. Reduced expressionl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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apoptotic agents [18]. DEK is thus implicated in several
essential oncogenic mechanisms, including both prolifera-
tion, differentiation and apoptosis.
Consistent with a role in these processes, DEK con-
tributes to cellular transformation. This has been most
strikingly demonstrated in keratinocytes, where cells
overexpressing DEK in addition to the HRAS, HPV E6
and E7 oncogenes display increased potential to form
colonies in soft agar and tumors when transplanted into
mice. The transformed cells are more sensitive to deple-
tion of DEK than the surrounding normal tissue, raising
the possibility of oncogene addiction and DEK as a drug
target. This notion is further supported by the finding
that DEK knockout mice are less prone to develop tu-
mors when challenged with carcinogens [19].
DEK is a structurally unique and highly conserved
protein with emerging roles in epigenetic and transcrip-
tional regulation. The DEK protein changes chromatin
topology by introducing positive supercoils and assem-
bles DNA and histones into chromatin [20,21]. It has
also been shown to sustain the levels of the repressive
histone mark H3K9me3 and inhibit several activating
histone acetyl transferases [22,23]. Concordantly, DEK
has been deemed essential for the preservation of tran-
scriptionally inactive heterochromatin [22]. However,
immunofluorescent imaging as well as immunoprecipita-
tion shows accumulation of DEK in regions of transcrip-
tionally active euchromatin [20,24]. The reported roles
of DEK in transcriptional regulation are similarly para-































































































Figure 1 DEK binding accumulates at transcription start sites. Distribu
start sites of the bound genes, across 150000 bp (A) and 4000 bp (B). (C) T
sequences as control. (D) Specificity of the ChIP-seq antibody, as demonstr
the expected size of the DEK protein, 43 kDa.SET, NFκB, P/CAF and p300 and is found in a repression
complex with Daxx [23,25-27]. But it is also a coactivator
of U2AF and the Drosophila ecdysone receptor, enhances
the transcriptional activity of AP-2α and C/EBPα, and ac-
cumulates during transcriptional activation of the CR2
gene [20,28-31]. To investigate the seemingly conflicting
reports on the geography of DEK binding and its role in
gene regulation, we performed a genome-wide analysis of
global DEK binding by ChIP-seq and knocked down DEK
with shRNA to analyze changes in gene expression. We
find that DEK binds to transcription start sites of highly
and ubiquitously transcribed genes and that DEK binding
can serve to either promote or repress transcription.
Results
DEK binds close to the transcription start site
For a genome-wide analysis of DEK binding, we per-
formed chromatin immunoprecipitation of DEK in the
U937 cell line followed by high-throughput sequencing
(ChIP-seq). We identified 4581 peaks of DEK binding,
determined as overlapping peaks in two independent
precipitations (Additional file 1: Table S1). The specifi-
city of the immunoprecipitating antibody was verified by
Western blot (Figure 1D). To determine the dispersion
pattern of DEK throughout the genome, we calculated
the distance from the middle of each DEK peak to the
nearest transcription start site (TSS). The result shows a
strong accumulation of DEK binding around the TSS
(Figure 1A-B). This was confirmed by analysis with the
Nebula software, showing that the highest enrichment of
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he types of genomic elements bound by DEK, with random genomic
ated by Western blot of U937 cell lysate showing a distinct band of
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To characterize the genes bound by DEK, we stratified
them based on their expression levels. All the genes in
the genome were assembled into groups of one thou-
sand, from the most to the least expressed genes based
on previously established expression levels in the U937
cell line, as determined by CAGE analysis [32]. For each
group, we then calculated the proportion of genes that
were bound by DEK. To exclude DEK binding which is
less likely to be relevant for gene regulation, we selected
the genes to which DEK binds within 1 kb from the
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Figure 2 DEK binds to highly expressed genes. Frequency of DEK bind
the U937 cell line for all genes in the genome were determined by Cap An
on their expression and grouped into bins of one thousand genes, with th
and the ones with the lowest expression in the rightmost column. For eac
be bound by DEK, showing that DEK binds most commonly to highly transcr
sites of genes with no (B), low (C), intermediate (D) and high (E) expression.using other or no boundaries. The result clearly demon-
strates that DEK mainly binds to highly transcribed
genes (Figure 2A). Furthermore, we divided all the DEK-
bound genes into four groups based on their expression;
no (CAGE 0), low (CAGE 0–10), intermediate (CAGE
10–100) and high (CAGE >100) expression. We then
calculated the distances from each DEK binding site to
the nearest transcription start site. Interestingly, the
genes that were not expressed lacked the characteristic
accumulation of DEK at the transcription start sites
(Figure 2B). And for the expressed genes, higher ex-
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ing to genes, based on their expression. Absolute expression levels in
alysis of Gene Expression (CAGE). The genes were then ordered based
e thousand genes with the highest expression in the leftmost column
h group, we calculated the proportion of the genes that were found to
ibed genes (A). Distribution of DEK peaks relative to the transcription start
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and gene transcription was further substantiated by
comparing the DEK binding pattern to those of previ-
ously characterized factors. We constructed an algo-
rithm that scored and ranked the binding patterns from
all 2642 ChIP-seq experiments in the Encode database
based on their similarity with the DEK binding pattern
(Additional file 2: Table S2). Strikingly, many of the most
similar binding patterns represented ChIP-seq analyses
of RNA polymerase II (POL2) binding, indicating active
gene transcription. This was visualized by ranking the
ChIP-seq experiments in Encode from most to least
similar to DEK, with POL2 experiments represented by
black bars (Figure 3A). The analysis clearly shows accu-
mulation of POL2 experiments among the patterns most
similar to that of DEK, with half of the 100 most similar
binding patterns belonging to POL2. The same result
was obtained when the analysis was conducted only with
Encode binding patterns established in myeloid cells
(Additional file 3: Table S3). In all four myeloid datasets,
the POL2 binding patterns were among the very most
similar to the DEK binding pattern (Additional file 4:
Table S4). The Encode database contains experiments
from a wide range of cells and tissues. Thus, the strikingOpen Chrom Synth binding patterns (black) am
from most similar (left) to least similar (r
A
B
Similarity to the DEK binding pattern
RNA PolymeraseII binding patterns (black) am
from most similar (left) to least similar 
Figure 3 DEK binding correlates with binding by RNA polymerase II a
experiments in the Encode database based on their similarity with the result o
was compared to the binding pattern of DEK and subsequently ordered from
pattern furthest to the left and the least similar pattern furthest to the right. (A
showing a strong enrichment of these binding patterns among the ones mo
Chip-seq experiment marking open chromatin, by synthesis of results from Ch
enrichment among the binding patterns most similar to that of DEK (p < 4×1similarity between DEK and POL2 binding across the
entirety of the database, as seen in Figure 3A, shows that
DEK binding is associated with genes that are commonly
transcribed across different cell types rather than tissue-
or lineage-specific genes. To confirm this notion, we
constructed figures as the one in Figure 3A for each
transcription factor in the Encode database. We then
calculated the similarity between the binding pattern of
each factor and the complete collection of POL2 experi-
ments, as the rank of the median POL2 experiment. Fi-
nally, we compared these scores with that of DEK. Out
of the 1172 analyzed binding patterns, only 39 had a
higher correlation with overall POL2 binding than DEK
did (Additional file 5: Table S5). With few exceptions,
the precipitated factor in these cases was POL2 itself.
DEK even ranked higher than 66% of the POL2 binding
patterns. This confirms that DEK binds to genes that are
not only highly expressed but also ubiquitously expressed
across different cell types.
DEK binds to open chromatin
Given the binding of DEK to highly expressed genes and
the implication of DEK in epigenetic regulation, we wanted
to characterize the epigenetic landscape of DEK binding,ong all binding pattern sin Encode ordered
ight) to the binding pattern of DEK
ong all binding pattern sin Encode ordered
(right)to the binding pattern of DEK
nd an open chromatin structure. Distribution of the 2642 ChIP-seq
f the DEK ChIP-seq. The binding pattern of every Encode experiment
left to right based on their similarity, with the most similar binding
) Each black line represents a Chip-seq experiment with RNA polymerase II,
st similar to that of DEK (p < 3×10−6). (B) Each black line represents a
IP-seq, FAIRE-seq and DNAse hypersensitivity analysis, showing strong
0−5).
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the Encode experiments termed OpenChromSynth, which
indicate regions of open chromatin, as determined by a
combination of ChIP-seq, FAIRE-seq and DNAse hyper-
sensitivity analysis. The result shows high similarity
between these genomic regions and the DEK binding pat-
tern (Figure 3B), suggesting extensive overlap between
DEK binding and regions of open chromatin. The same
result was obtained when the analysis was restricted to the
myeloid datasets (data not shown). To determine the his-
tone modifications associated with DEK binding, we cal-
culated the similarity between the DEK binding pattern
and those of the histone modifications analyzed in the
BroadHistone K562 dataset in Encode (Figure 4). In con-
cordance with binding to highly transcribed genes, DEK
showed the highest degree of overlap with the active TSS
marker H3K4me3, the active enhancer marker H3K27ac
and the active promoter markers H3K4me2 and H3K9ac
[33-36]. Conversely, the two repressive histone modifica-













Figure 4 DEK binding correlates with activating histone marks. Similarity
from the Broad Histone K562 dataset in Encode, showing the highest similarit
the two repressive histone marks (grey bars).with the least overlap [37]. The association between DEK
and active chromatin was further demonstrated by per-
forming a DNA methylation array to calculate the methy-
lation grade for each gene. The methylation of the genes
bound by DEK was then compared to the global gene
methylation. The result shows markedly lower methyla-
tion of the genes to which DEK binds (Figure 5). Thus,
consistent with the binding to the transcription start sites
of highly and commonly transcribed genes, we also find
that DEK binds to regions of open chromatin with low
DNA methylation and which are rich in activating histone
marks.
DEK binding is enriched among certain sets of genes
The results above show that DEK binds to genes com-
monly expressed in different cell types and tissues. This
was further confirmed by gene ontology analysis of the
genes to which DEK binds within 1000 bp of the tran-
scription start site. The significantly enriched categories
mainly represent basic metabolic processes that are.02 0.03 0.04 0.05
the DEK binding pattern
between the DEK binding pattern and those of ChIP-seq experiments
y with activating histone marks (black bars) and the lowest similarity with





















Figure 5 DEK binds to lowly methylated DNA. DNA methylation grade for the genes bound by DEK (black line) and the complete genome
(grey line), showing lower methylation for the DEK-bound genes, as determined by DNA methylation array analysis of U937 cells.
Table 2 DEK binds to DNA with motifs for major
transcriptional regulators
Motif Motif e value Match Match P value
AGGAARH 1.5 × 10−41 PU.1 0.000013
DAAATR 5.6 × 10−22 - -
−20
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quently deregulated in cancer and essential for cancer
cell proliferation, such as protein synthesis and cell cycle
regulation. Notably, the category with the highest enrich-
ment of DEK-bound genes is “Nucleosome assembly”, a
process in which DEK itself is directly and functionally im-
plicated [38]. This suggests that DEK could contribute to
epigenetic regulation not only directly but also by binding
and regulating other genes involved in the process. Gene
ontology analysis of the genes deregulated by knockdown
of DEK in U937 cells by shRNA shows that many of the
genes whose expression is affected by DEK are involved in
the same processes, such as cell cycle and chromatin regu-
lation (Additional file 6: Table S6). Since no binding motifTable 1 DEK binds to genes involved in multiple cellular
functions
Gene ontology term Fold
enrichment
P value
Nucleosome assembly 5.96 2.7 × 10−6
mRNA metabolic process 2.95 1.8 × 10−8
RNA splicing 2.82 5.3 × 10−3
Ubiquitin-dependent protein catabolic process 2.59 4.9 × 10−3
Cellular macromolecular complex assembly 2.58 5.0 × 10−5
Viral process 2.34 7.2 × 10−4
Interspecies interaction between organisms 2.20 2.8 × 10−3
Protein complex biogenesis 2.16 7.9 × 10−5
Cell cycle 1.84 4.7 × 10−4
Cellular catabolic process 1.70 2.5 × 10−3
Gene expression 1.41 5.0 × 10−4
Gene ontology analysis of the DEK-bound genes, showing enrichment in many
categories that are central for cancer biology.has been defined for the DEK protein, we analyzed the
DEK-bound sequences for enriched motifs (Table 2). The
identified motif with the highest degree of significance was
found to be a binding motif for the transcription factor
PU.1, a key regulator of gene expression during myeloid
cell development and highly expressed in these cells. TheCMCMGCC 9.3 × 10 SP1 0.000019
ACACASR 1.3 × 10−18 - -
KTTTCY 1.5 × 10−13 - -
CHGCMGCC 6.7 × 10−12 - -
CTTCCBS 3.0 × 10−9 PU.1 0.000006
CAGCKCC 1.0 × 10−8 - -
TWTAWA 3.4 × 10−8 - -
MTGTGGY 6.9 × 10−6 RUNX1 0.000017
CACGTG 4.5 × 10−5 USF1 0.000001
CCCCACCC 3.5 × 10−3 SP1 0.000044
CTGTCACY 7.6 × 10−3 - -
Motif analysis of the sequences bound by DEK, identifying the most common
motif not as a unique DEK motif but as that of the transcription factor PU.1.
The motif E value denotes the statistical significance of the enrichment of the
motif among the DEK-bound sequences. The match p value denotes the
statistical significance of the match between the enriched motif and that of
the matching transcription factor. Nucleotide sequences are described using
standard IUPAC nomenclature, where B denotes C/G/T, D denotes A/G/T,
H denotes A/C/T, K denotes G/T, M denotes A/C, R denotes A/G, S denotes C/G,
W denotes A/T and Y denotes C/T.
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SP1, RUNX1 and USF1, all of which are also expressed in
these cells. Although we also identified several motifs not
corresponding to known transcription factors, it is unlikely
that any of these represent genuine DEK motifs, since
none of them predict DEK binding as well as the PU.1
motif.
DEK binding correlates with gene expression
The role of DEK in gene regulation is far from under-
stood. Previous studies have determined both activating
and repressive effects on the expression of single genes.
To study the effect on a genome-wide scale, we com-
bined the results of the ChIP-seq analysis with gene ex-
pression microarray analysis following knockdown of
DEK by shRNA. Based on the microarray analysis, we
characterized the DEK-bound genes as either upregu-
lated, downregulated or unaffected by the knock-down
of DEK (Additional file 7: Table S7). To only include the
DEK binding most likely to influence gene expression,
the analysis was limited to genes where DEK binds less
than 1000 bp either upstream or downstream from the
transcription start site. Compared to the complete gen-
ome, significantly more genes were found to be either
upregulated or downregulated by DEK depletion than
unaffected. The same result was obtained when either
fold change (Figure 6A, E) or statistical significance
(Figure 6B) were used as the measure of change in gene
expression. The same pattern was observed when DEK
was knocked down in primary CD34+ cells isolated from
human umbilical cord blood (Figure 6C-D). That the
correlation is not as strong for the primary cells is ex-
pected, given the discrepancy in gene expression between
these cells and the U937 cell line in which the ChIP-seq
analysis was performed. These findings emphasize the role
of DEK as a gene regulatory protein and indicate that
DEK serves as both an activator and a repressor of tran-
scription in the same cell under the same conditions. To
validate the association of DEK binding with gene expres-
sion, we performed a network analysis of a collection of
publicly available microarray datasets from patients with
acute myeloid leukemia. For all of the 1246 analyzed tran-
scription factors, we calculated the number of genes
whose expression correlated with that of each transcrip-
tion factor (Table 3). Interestingly, DEK was found to be
the factor with the third highest number of correlated
genes. The analysis was then repeated using microarray
data from the Microarray Innovations in Leukemia
(MILE) study [39]. In this analysis, DEK ranked in the 11th
percentile and out of the 30 factors with the most connec-
tions in the original dataset, DEK was the one with the
most connections in the MILE dataset. Taken together,
the network analyses underscore the importance of DEK
in gene regulation.Discussion
This study provides a genome-wide map of DEK binding
in myeloid cells. We show that DEK does not bind uni-
formly to long stretches of the genome, as previously
suggested by the high amounts of DEK bound to chro-
matin [21]. Instead, we demonstrate that DEK binding is
highly distinct and centered around transcription start
sites. We continue to show that DEK mainly binds to
highly expressed genes and that the accumulation of
binding around the transcription start site positively cor-
relates with the transcription of the gene. These findings
are in concert with a previous study of a single gene
locus, which found that DEK binding to the promoter of
the complement receptor 2 gene is 2–3 fold higher in a
cell line expressing the gene than in a cell line without
expression and in which DEK was shown to be recruited
to the promoter upon induction of gene expression [29].
Furthermore, our findings are consistent with previous
reports that DEK contributes to positive supercoiling of
the DNA structure, which opens up the chromatin to
allow access to the transcriptional machinery and is a
characteristic of highly transcribed genes [21,40]. The
correlation between DEK binding and gene expression is
further underlined by our finding that out of the 2642
binding patterns in the Encode database, the DEK bind-
ing pattern is most similar to that of RNA polymerase II.
Interestingly, we found that the DEK binding pattern
not only resembles that of RNA polymerase II in
hematopoietic cells but also in highly different cell types.
In a comparison with the complete collection of POL2
bindings patterns in Encode, DEK was one of the factors
with the highest degree of similarity. The DEK binding
pattern actually scored higher than most POL2 binding
patterns in terms of similarity with overall POL2 bind-
ing. This shows that DEK binds to genes that are com-
monly expressed across cell types, which could explain
the ubiquitous expression of DEK in human tissues.
Genes that are expressed in very different cell types gen-
erally contribute to common functions such as cellular
organization and metabolism. Gene ontology analysis
confirmed that genes bound by DEK are involved in
basic cellular functions such as catabolism, biogenesis
and chromatin organization. Many of these processes
are not only fundamental to normal cells but must also
be deregulated in order for cancer cells to produce the
macromolecules and the energy needed for their high
proliferation. Accelerating basic cellular functions could
thus be a way by which DEK contributes to carcinogen-
esis. This notion would be compatible with the previous
observation that DEK is essential for tumor cells but dis-
pensable for their normal counterparts [19]. We also
show that DEK binds to genes involved in cell cycle
regulation and gene expression, processes with obvious




Figure 6 Genes bound by DEK are both up- and downregulated by the knockdown of DEK. Proportion of genes that are bound by DEK
among the genes that were upregulated, downregulated and not affected by the knockdown of DEK. Both the downregulated and the upregulated
genes are enriched for DEK-bound genes, showing that DEK binding is associated with transcriptional regulation and may contribute to both
promotion and repression of gene transcription. The downregulated and upregulated categories were defined as the thousand most up- and
downregulated genes based on either fold change (A and C) or p value (B and D), as determined by gene expression microarray analysis of U937
(A and B) and primary CD34+ cord blood cells (C and D). (E) Cumulative distribution frequency of genes based on their fold change in gene expression
upon knockdown of DEK in U937 cells, showing enrichment of DEK-bound genes both among the genes most upregulated and the genes most
downregulated by DEK depletion. (F) The efficiency of the shRNA-mediated knockdown of DEK in U937 and primary CD34+ cord blood cells, as
determined by Western blot. Histone H3 was used as an equal loading control.
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Table 3 DEK expression correlates with the expression of
other genes














Network analysis of gene expression in publicly available datasets, showing
DEK as one of the transcription factors whose expression has the most
correlations to the expression levels of other genes. The ten transcriptions
factors with the most correlations in the AML network are shown.
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transformed cell lines, some of the commonly expressed
genes encode the proteins conferring the cancer pheno-
type. We show that the genes bound by DEK are also
enriched for genes involved in cell cycle regulation and
gene expression, which could mediate the oncogenic func-
tion of DEK.
Previous studies have provided contradictory indica-
tions regarding the association of DEK with euchromatin
and heterochromatin. Based on immunofluorescence
imaging, DEK co-localizes with regions of open chroma-
tin containing acetylated histone H4 [24]. It also co-
precipitates with the activating histone marks H3K4me2
and H3K4me3 [20]. Contrarily, other reports have indicated
DEK as essential for the maintenance of heterochromatin
by strengthening the binding between heterochromatin
protein 1α and the heterochromatin marker H3K9me3
[22]. Here, we show that DEK binding overlaps with his-
tone marks found in euchromatin and with genes carry-
ing a low degree of DNA methylation. We thus conclude
that DEK preferentially binds to euchromatin and more
specifically to transcription start sites of euchromatic
genes.
DEK has been shown to bind to chromatin in a man-
ner dependent on the structure rather than the sequence
of the DNA, based on the finding that DEK accumulates
at sites of supercoiled and four-way junction DNA [41].
However, sequence-specific binding to the peri-ets site
of the HIV-2 enhancer has been demonstrated [42]. To
determine the sequence-specificity of the genome-wide
DEK binding, we performed motif analysis of the bound
sequences. The analysis identified the most significantly
enriched motif as that of the hematopoietic transcription
factor PU.1. However, given that PU.1 is a majortranscription factor in these cells, many of its target
genes coincide with the highly expressed genes bound
by RNA polymerase II. Since the comparison with the
Encode experiments shows that the binding pattern of
DEK is more similar to the binding pattern of RNA
polymerase II than to that of PU.1, it is more likely that
the binding to genes with PU.1 motifs is a consequence
of their high expression than that PU.1 would be the
major determinant of DEK binding. We also identified
several previously uncharacterized motifs. However, it is
unlikely that any of these is a common DEK motif as
none of them were nearly as significantly enriched as
the PU.1 motif. Thus, we find that DNA sequence does
not predict DEK binding as well as gene expression.
The role of DEK binding in gene expression is still
ambiguous, with reports of contributions to either acti-
vation or repression of single genes under different con-
ditions. Our finding that knockdown of DEK leads to
both upregulation and downregulation of DEK-bound
genes suggests that DEK has a dual role in gene regula-
tion in that it can either promote or repress transcrip-
tion of different genes in the same cellular context. The
determinants of the effect of DEK on transcription are
still unknown but could potentially include phosphoryl-
ation by casein kinase 2, which has been shown to alter
but not abolish the association between DEK and chro-
matin [43]. Another possible model is one where DEK
contributes to either activation or repression depending
on the cofactors that bind at the gene regulatory site.
To further examine the importance of DEK in gene
regulation in primary leukemic cells, we constructed a
network model of gene expression and found that out of
the 1246 analyzed factors, DEK was the factor with the
third highest number of correlated genes. This suggests
that DEK may have a broad set of targets, consistent
with our findings that DEK binds to many highly and
commonly expressed genes. Furthermore, it strongly
suggests that DEK is important for gene regulation and
may play a major role in the gene regulatory pathways
that govern cancer cells. Characterizing the precise
mechanistics of DEK-mediated gene regulation will be
an important challenge for future research and a key to
understanding the role of DEK in cancer biology and its
potential as a therapeutic target.
Materials and methods
Cell culture
The U937 cell line (ATCC, Manassas, VA, USA) was cul-
tured in RPMI 1640 medium (Life Technologies, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum
(Life Technologies). Primary CD34+ cells were obtained
from human umbilical cord blood collected at Skåne Uni-
versity Hospital. The mononuclear cell population was
isolated by separation on Lymphoprep (Axis-Shield PoC
Sandén et al. Molecular Cancer 2014, 13:215 Page 10 of 13
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lected using the Indirect CD34 MicroBead Kit (Miltenyi
Biotec, Bergisch Gladbach, Germany). The cells were
grown in StemSpan SFEM medium (Stemcell Technolo-
gies, Vancouver, Canada) supplemented by 20% fetal bo-
vine serum and the CC100 cytokine cocktail (Stemcell
Technologies).
ChIP-seq
Chromatin immunoprecipitation was performed on U937
cells using the Magna-ChIP A/G Chromatin Immunopre-
cipitation Kit (Merck Millipore, Billerica, MA, USA) after
crosslinking with 1% formaldehyde for 15 min. Chromatin
shearing was achieved by sonication in a Bioruptor UCD-
200 (Diagenode, Liège, Belgium). Immunoprecipitation
was performed with 10 μg of DEK antibody (Abcam,
Cambridge, UK; product code ab74975) per million cells.
Immunoprecipitated DNA was sequenced by the Science
for Life Laboratory in Stockholm, Sweden with an Illu-
mina HiSeq 2000 as paired-end reads to 100 bp with a
minimum of 18 million reads per sample. The Illumina
OLB v1.9 was used for base conversion, the Bowtie 2 soft-
ware [44] was used for the alignment of reads to the hg19
reference genome and peak calling was performed with
the MACS software v1.4.1 [45]. Default parameters were
used throughout the process. Two independent ChIP-seq
experiments were performed under identical conditions
and the peaks found in both experiments were used for all
subsequent analyses. Non-precipitated chromatin was
used as negative control. Validation was performed by
real-time PCR analysis of DNA immunoprecipitated with
the DEK antibody, showing enrichment of DNA corre-
sponding to the predicted binding sites in the S100A9
(fold enrichment 2.4) and VIM (fold enrichment 1.8)
genes and a lack of enrichment of DNA corresponding to
the IRF8 gene (fold enrichment -3.1), which was deter-
mined by the ChIP-seq analysis to not be bound by DEK.
The raw data from the ChIP-seq analysis is available
through the Gene Expression Omnibus data repository,
with the accession number “GSE60692”.
Binding to genomic elements
The “Genomic annotation of ChIP-seq peaks” tool in the
Nebula software package [46] was used with default pa-
rameters to find the closest gene to each DEK peak and
calculate the distance from the transcription start site to
the middle of the peak. The same tool was used to deter-
mine the genomic elements to which DEK binds, using
default settings where promoters are designated as the
2.000 bp upstream of the transcription start site and en-
hancers are designated as the 30.000 bp upstream of the
TSS. As control, random genomic sequences were gen-
erated by a random draw with replacement from a
square-distribution across all genomic positions.Cap analysis of gene expression
Absolute gene expression levels for all genes in the U937
cell line were determined by Cap Analysis of Gene Ex-
pression (CAGE) in a study by the FANTOM5 consor-
tium [32]. All genes were ordered by absolute expression
and divided into bins of one thousand, for which we cal-
culated the number of genes where DEK binds within
1000 bp from the transcription start site. For further
analysis, all DEK-bound genes were divided into four
categories according to their expression; no (0), low (0–
10), intermediate (10–100) or high (>100) expression.
For each category, the distances to the nearest transcrip-
tion start sites were calculated as described above.Correlation with existing ChIP-seq binding patterns
The determined DEK binding pattern was compared to
the binding patterns previously established for transcrip-
tion factors and histone modifications as well as the
genome-wide distributions of characteristics such as
DNAse hypersensitivity. To this end, we constructed an
algorithm which analyzed all of the 2642 such patterns
in the Encode database and scored them based on their
similarity with the binding pattern of the DEK protein.
For each Encode binding pattern, the weight of each
base was calculated based on the number of sequence
tags at that position in the genome. The raw correlation
between this sequence tag distribution and that of DEK
was then calculated as the sum of the products of the
weights of each matching base, corrected for track

















where weight1i and weight2i are the score assigned
basepair i in the two tracks compared, respectively, and
nbasepairs is the total number of basepairs in the hg19
assembly of the human genome. DEK binding was corre-
lated with open chromatin status by comparison of the
DEK binding pattern with the Encode tracks designated
OpenChromSynth, each containing a synthesis of results
from ChIP-seq, FAIRE-seq and DNAse hypersensitivity
analysis in the examined cell type. The binding patterns
of different histone marks in the K562 cell line were
obtained from the Broad Histone dataset in Encode.
Statistical testing of the enrichment of tracks representing
either RNA polymerase II or OpenChromSynth among
the most similar binding patterns to that of DEK was
performed using the RenderCat software, as previously
described [47].
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Microarray-based DNA methylation analysis was per-
formed with the Infinium HumanMethylation27 BeadChip
(Illumina) by the BEA core facility at Karolinska Institute.
Genomic DNA from U937 cells was extracted using the
QIAamp DNA mini kit (Qiagen) and bisulfite converted
using the Zymo EZ DNA methylation Kit (Zymo Re-
search, Irvine, CA). Subsequently, the DNA was subjected
to the Illumina Infinium HD Methylation assay including
whole genome amplification and enzymatic fragmentation
before hybridization to the BeadChip. Arrays were
scanned and the signals processed in Genome Studio
module 1.8. The methylation grade for each gene was cal-
culated as the average of the corresponding probes. The
methylation of the genes to which DEK binds within
1000 bp of the transcription start site was then compared
to the methylation of the entire genome. The raw data
from the DNA methylation analysis is available through
the Gene Expression Omnibus data repository, with the
accession number “GSE60734”.
Knockdown of DEK by shRNA
Two shRNAs in H1 lentiviral vectors targeting the DEK
transcript were a kind gift from Dr David Markovitz [2].
Lentiviral particles were harvested after calcium phos-
phate transfection of 293 T cells (ATCC) with the re-
spective shRNA constructs, gag-pol and the RD114
envelope gene. For lentiviral transduction, non-tissue
culture coated plates were coated with retronectin
(Takara, Otsu, Japan) and blocked with 2% bovine serum
albumin (Sigma-Aldrich, St. Louis, MO, USA) for 30 min
at room temperature. Subsequently, virus-containing
medium was added and the plates were centrifuged at
1000 × g for 60 min at 4°C before the cells were added
and incubated at 37°C for 48 h, after which they were
sorted by FACS based on the expression of the GFP
marker. Transduction efficiencies were similar for all con-
structs and consistently above 40%. The efficiency of the
knockdown was verified by Western blot of cell lysates ob-
tained 4 days (U937 cells) or 10 days (primary cells) after
sorting, with a primary DEK antibody (BD Transduction
Laboratories, San Jose, CA, USA). The raw data from the
gene expression analysis is available through the Gene Ex-
pression Omnibus data repository, with the accession
number “GSE60734”.
Gene expression microarray
RNA was isolated with the RNeasy Mini Kit (Qiagen,
Hilden, Germany) from cells harvested 4 days (U937) or
10 days (primary cells) after sorting. Microarray analysis
was performed in triplicates with the HumanHT-12 v4
Expression BeadChip (Illumina, San Diego, CA, USA) by
the Swegene Centre for Integrative Biology at Lund
University (SCIBLU). Designated as upregulated ordownregulated were the genes found to be among the
thousand most strongly upregulated or downregulated
based on either the average fold change or the combined
p value from statistical testing of the two shRNA con-
structs by the student’s t test. Subsequently, the number
of genes to which DEK binds within 1000 bp from the
transcription start site was calculated for each category.
The gene expression microarray was validated by quanti-
tative real-time PCR analysis of two genes found to be
upregulated (CSF2RA; fold change 1.3, p = 0.004 and
CSF3R; fold change 1.3, p = 0.04) and two genes found
to be downregulated (CHMP2B; fold change −1.3, p =
0.03 and ICAM2; fold change −1.4, p = 0.002) upon
knockdown of DEK in the U937 cell line. For this ana-
lysis, RNA was reverse-transcribed to cDNA with the
High Capacity cDNA Reverse Transcription Kit (Life
Technologies) and real-time PCR was performed using
the TaqMan Gene Expression Assay (Life Technologies)
and the StepOne Plus Real-Time PCR System (Life
Technologies).
Gene ontology analysis
Gene ontology analysis of the genes bound by DEK was
performed with the GO::TermFinder software [48], using
gene ontology associations based on the UniProt refer-
ence proteome. The analysis was performed on the
genes to which DEK binds within 1000 bp from the
transcription start site, with the default p value threshold
of 0.01. Fold enrichment was calculated as the percent-
age of the DEK-bound genes associated with a certain
term divided by the percentage of the total genome asso-
ciated with the same term. The result was filtered for re-
dundant terms and terms containing more than 5000
genes. Gene ontology analysis of the genes deregulated
by the knockdown of DEK was performed by Gene Set
Enrichment Analysis (GSEA), using a p value threshold
of 0.01 and a false discovery rate threshold of 0.05 [49].
Motif analysis
Motif analysis was performed with the Discriminative
Regular Expression Motif Elicitation (DREME) software
[50], using as input the sequences from 150 bp upstream
to 150 bp downstream of the middle of all DEK peaks.
The p value threshold was set to 0.01. Identified motifs
were subsequently matched with known motifs using the
TOMTOM software [51] with a false discovery rate
threshold of 5%.
Network analysis
The genome-wide AML network of gene expression was
constructed by LASSO regression modeling of gene ex-
pression correlations in 3013 samples obtained by merging
samples from studies based on the Affymetrix HG-U133
Plus 2.0 GeneChips (GPL570) platform (see Additional
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network was constructed in the same manner but instead
based on the results from stage one of the Microarray In-
novations in Leukemia study [39]. To reduce the false dis-
covery rate, the correlation threshold of the network
models was set to a level at which they did not find any
correlations in randomized data. The list of transcription
factors used in the analysis was manually curated after its
original development as part of the Differentiation Map
project [52].
Additional files
Additional file 1: Table S1. DEK Binding Sites. Complete list of
significant peaks of DEK binding, as determined by ChIP-seq analysis in
the U937 cell line.
Additional file 2: Table S2. Correlation between the binding pattern of
DEK and those of other factors. Complete list of all 2642 ChIP-seq experiments
in the Encode database, ordered from that with the most to that with the
least similar binding pattern to that of DEK.
Additional file 3: Table S3. Correlation between the binding pattern of
DEK and those of other factors in myeloid cells. Complete list of the 201
ChIP-seq experiments in the Encode database that were performed in
myeloid cells, ordered from that with the most to that with the least
similar binding pattern to that of DEK.
Additional file 4: Table S4. DEK binding correlates with RNA polymerase
II binding in hematopoietic datasets. All ChIP-seq experiments in the four
hematopoietic datasets in the Encode database were scored and ranked
based on their similarity with the DEK binding pattern. In all four datasets,
the binding patterns of RNA polymerase II were among the most similar to
that of DEK.
Additional file 5: Table S5. DEK binds to commonly expressed genes.
Complete list of the 1172 analyzed transcription factors, based on their
binding to genes that are commonly expressed across different tissues.
For each transcription factor, the overlap with each of the other binding
patterns in the Encode database was calculated. The resulting ranks of
the POL2 binding patterns were extracted and the median rank was
calculated, representing the similarity between the binding pattern of the
transcription factor and that of POL2 across all the different cell types
represented in Encode. DEK was found to be one of the transcription
factors with the highest similarity, demonstrating that DEK binds to
genes that are commonly expressed across different cell types.
Additional file 6: Table S6. DEK affects the expression of genes
involved in multiple cellular functions. Gene set enrichment analysis of
the changes in gene expression following knockdown of DEK, showing
that the genes deregulated upon DEK knockdown are involved in
multiple cellular processes that are also enriched for genes shown in
Table 1 to be bound by DEK. Positive enrichment scores correspond to
enrichment among the genes downregulated by DEK knockdown and
negative enrichment scores correspond to enrichment among the genes
upregulated by DEK knockdown. FDR denotes the false discovery rate.
Additional file 7: Table S7. DEK affects gene expression. Complete list
of changes in gene expression upon knockdown of DEK by shRNA in the
U937 cell line, as determined by microarray analysis.
Additional file 8: Datasets used for the network analysis.
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